At times, it is necessary to ''neutralize'' the opposition, or at least Merck & Company executives seemed to think so.
In 1999, the company's new pain drug, Vioxx, was beaten to pharmacy shelves by a competing drug, Celebrex. Merck apparently hoped that nationally known rheumatologists like Dr. Roy Altman could help it catch up.
